We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Illumina Announces Collaboration with top Five Pharmaceutical Companies

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Illumina Announces Collaboration with top Five Pharmaceutical Companies"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Illumina, Inc. has announced a multi-million dollar agreement with one of the top five pharmaceutical companies for the purchase and installation of a multi-component genetic analysis system.

Depending on the Illumina arrays being processed, this system will be capable of generating over 45 million genotypes per day, and will represent a core support facility for the company's global research teams.

The Illumina genetic analysis system is designed to run both genotyping and gene expression applications and will include a number of scanners and robotic components for automated sample and array processing.

An initial project involving 3,200 samples will be run using Illumina's Infinium® Assay and the HumanHap650Y BeadChip, which provide genomic coverage and the per-marker information content of any whole-genome genotyping arrays.

"We are excited that the pharmaceutical industry is adopting large-scale genotyping and that Illumina is at the forefront of this new technology," said Jay Flatley, Illumina President and CEO.

"This demonstrates that genotyping has become a robust discovery method and is now poised to move more routinely into clinical development to support pharmacogenomic and predictive diagnostic applications."